Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Current Liabilities (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Total Current Liabilities for 7 consecutive years, with $32.5 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 8.47% to $32.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.5 million through Dec 2025, down 8.47% year-over-year, with the annual reading at $32.5 million for FY2025, 8.47% down from the prior year.
  • Total Current Liabilities hit $32.5 million in Q4 2025 for Allogene Therapeutics, up from $31.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $59.4 million in Q1 2023 to a low of $30.0 million in Q1 2025.
  • Historically, Total Current Liabilities has averaged $41.8 million across 5 years, with a median of $37.4 million in 2023.
  • Biggest YoY gain for Total Current Liabilities was 104.52% in 2021; the steepest drop was 49.21% in 2021.
  • Year by year, Total Current Liabilities stood at $47.9 million in 2021, then grew by 12.15% to $53.7 million in 2022, then plummeted by 30.99% to $37.1 million in 2023, then decreased by 4.2% to $35.5 million in 2024, then decreased by 8.47% to $32.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for ALLO at $32.5 million in Q4 2025, $31.8 million in Q3 2025, and $31.7 million in Q2 2025.